Retatrutide
Evidence: B+ — Meaningful Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
Strong phase 2 human evidence and multiple positive phase 3 sponsor-reported findings for obesity and type 2 diabetes; still investigational, with incomplete long-term outcome and regulatory evidence.
Regulatory Context
Investigational triple-receptor agonist in Phase 3 clinical development by Eli Lilly and Company. Retatrutide is not approved by the FDA or any other regulatory agency as of July 20, 2026. Completion or reporting of clinical trials does not constitute marketing authorization.
Research Takeaway
Retatrutide is the development molecule LY3437943, a single peptide agonist at the GIP, GLP-1, and glucagon receptors.
See all 17 evidence claims →Quick Summary
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist in Phase 3 development. Human trials report substantial effects on body weight and glucose control, with additional research in liver fat and obesity-related complications. It remains unapproved, and long-term cardiovascular outcomes, uncommon risks, maintenance after treatment, and real-world product quality remain unresolved.
Mechanism & Research Overview
Retatrutide is a single modified peptide engineered to activate the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor. These are class B G-protein-coupled receptors that primarily signal through cyclic AMP. The combined design is intended to integrate incretin-driven glucose regulation and appetite effects with glucagon-receptor activity that can increase hepatic substrate mobilization and energy expenditure. The contribution of each receptor cannot be inferred from clinical outcomes alone because all three activities are delivered by the same molecule.
Read more about the mechanism
GLP-1 receptor activation supports glucose-dependent insulin secretion, reduces glucagon secretion during hyperglycemia, slows gastric emptying, and promotes satiety. GIP receptor activation also enhances glucose-dependent insulin secretion and may modify nutrient handling in adipose and other tissues. Glucagon receptor activation can raise hepatic glucose output, but in a balanced multi-receptor agonist it is being studied for possible effects on energy expenditure and lipid metabolism while the incretin components counter excessive glycemic effects.
The peptide contains amino-acid substitutions and a lipid-linked side chain designed to resist rapid enzymatic degradation and support prolonged exposure. In an early clinical study, its pharmacokinetic profile supported once-weekly administration in research settings. Receptor activity, pharmacokinetics, and observed weight or glucose changes do not establish which mechanism dominates in an individual or prove long-term cardiovascular, hepatic, renal, or musculoskeletal benefit.
Evidence Grade Breakdown
A single letter grade can't capture how evidence quality differs across approved use, off-label use, and unsupported claims. The categories below break that down -- none of them grade this compound "overall."
Overall Research Grade
Retatrutide has strong randomized human evidence for substantial weight reduction and metabolic effects in adults with obesity or type 2 diabetes, supported by a clearly characterized triple-receptor mechanism. However, it remains investigational, lacks final regulatory approval, and has incomplete long-term cardiovascular, safety, durability, and real-world evidence.
BRegulatory and Development Evidence
Confidence: High
Scope: Applies to the documented investigational development program, not to unapproved commercial products or compounded versions.
Show detail
Regulatory and Development Evidence
Retatrutide has advanced through multiple randomized clinical-development studies with publicly documented trial programs, but it remains investigational and is not an FDA-approved treatment.
Why this grade
- Active late-stage clinical-development program
- Multiple completed randomized human trials
- Published phase 2 efficacy and safety data
- Clearly defined investigational indication and development pathway
- Public clinical-trial records and primary publications
Important limitations
- No FDA-approved prescribing information
- No approved commercial indication
- Phase 3 outcomes may remain incomplete or unpublished
- Regulatory conclusions may change as development progresses
A-Human Clinical Evidence
Confidence: High
Show detail
Human Clinical Evidence
Randomized human studies demonstrate substantial dose-dependent weight reduction and improvements in metabolic measures in adults with obesity and type 2 diabetes. The evidence is strong for short- to medium-term efficacy, but long-term clinical outcomes and broader population evidence remain incomplete.
Why this grade
- Multiple randomized controlled human trials
- Dose-response evidence
- Clinically substantial weight-loss outcomes
- Evidence in obesity and type 2 diabetes populations
- Consistent direction of metabolic effects
Important limitations
- Limited long-term follow-up
- Incomplete evidence for cardiovascular outcomes
- Limited real-world evidence
- Selected trial populations may not represent all users
- Durability after discontinuation remains uncertain
A-Mechanistic Evidence
Confidence: High
Show detail
Mechanistic Evidence
Retatrutide is a single-molecule agonist of the GIP, GLP-1, and glucagon receptors. Its receptor pharmacology and associated metabolic effects are supported by preclinical and human clinical research, although the contribution of each receptor to long-term clinical outcomes is not fully resolved.
Why this grade
- Defined triple-receptor agonist design
- Characterized GIP-receptor activity
- Characterized GLP-1-receptor activity
- Characterized glucagon-receptor activity
- Consistent metabolic effects in preclinical and human studies
Important limitations
- Receptor activity does not independently establish every claimed clinical outcome
- Relative contribution of each receptor remains partly uncertain
- Long-term physiologic consequences require additional evidence
- Mechanistic evidence does not validate unapproved formulations
BSafety Evidence
Confidence: Moderate
Show detail
Safety Evidence
Randomized trials provide meaningful short- and medium-term safety data, particularly for gastrointestinal adverse effects and treatment discontinuation. Long-term safety, cardiovascular outcomes, rare adverse events, and broader real-world risks remain unresolved.
Why this grade
- Randomized clinical-trial safety reporting
- Dose-related gastrointestinal adverse-event data
- Treatment-discontinuation data
- Vital-sign and metabolic monitoring
- Multi-dose clinical exposure
Important limitations
- No approved prescribing label
- Limited long-term exposure
- Rare adverse events may not yet be detectable
- Cardiovascular safety remains under evaluation
- Limited pregnancy, older-adult, renal, hepatic, and complex-comorbidity data
- Safety of unregulated products is not established
DOff-Label and Extrapolated Evidence
Confidence: Moderate
Show detail
Off-Label and Extrapolated Evidence
Evidence does not establish retatrutide for uses outside its formal clinical-development populations and outcomes. Claims involving anti-aging, generalized metabolic optimization, addiction, cognitive enhancement, bodybuilding, or other conditions remain unsupported or highly preliminary.
Why this grade
- Strong evidence is concentrated in obesity and type 2 diabetes trials
- Limited evidence exists outside formal development populations
- Mechanistic plausibility is sometimes extrapolated beyond clinical data
Important limitations
- No approved off-label use exists because the drug remains investigational
- Trial outcomes should not be generalized to unrelated diseases
- No established evidence for athletic performance or body recomposition in healthy athletes
- No established evidence for anti-aging or longevity
FBiohacking and Wellness Claims
Confidence: High
Show detail
Biohacking and Wellness Claims
Current evidence does not establish retatrutide as a general wellness, anti-aging, longevity, bodybuilding, cognitive-enhancement, or self-directed biohacking intervention.
Why this grade
- No regulatory approval for wellness use
- No randomized evidence for anti-aging
- No established longevity outcomes
- No established bodybuilding or athletic-performance indication
- No established cognitive-enhancement indication
Important limitations
- Absence of evidence does not prove every proposed effect impossible
- Mechanistic speculation is not equivalent to demonstrated benefit
- Unregulated-product quality and safety cannot be inferred from clinical trials
Evidence reviewed
Investigational retatrutide development, triple-receptor pharmacology, randomized obesity and type 2 diabetes trials, weight and metabolic outcomes, safety, regulatory status, and unsupported extrapolated wellness claims.
- Randomized human trials
- 7
- Primary sources reviewed
- 10 of 11
- Last literature review
- July 20, 2026
Study counts describe the reviewed evidence base. They do not independently determine evidence quality.
How MitoCore grades evidence
Grade definitions
- A
- Strong and directly applicable evidence, generally including regulatory support or multiple high-quality replicated human trials for the exact claim and population.
- A-
- Strong human evidence with limited uncertainty, narrower applicability, or incomplete replication.
- B+
- Moderately strong evidence with meaningful human support but important scope, duration, safety, or generalizability limitations.
- B
- Credible evidence with notable uncertainty, limited replication, or mixed results.
- C
- Preliminary or inconsistent evidence, usually limited human data or strong indirect evidence.
- D
- Weak, indirect, population-limited, or largely unsupported evidence for the specific use being graded.
- F
- No credible supporting evidence, evidence contradicting the claim, or claims based primarily on speculation or marketing.
Confidence definitions
- High
- The evidence classification is unlikely to change substantially with ordinary additional research.
- Moderate
- The classification is reasonably supported but could change with additional high-quality evidence.
- Low
- The evidence base is sparse, indirect, inconsistent, or dependent on uncertain assumptions.
- Very Low
- The evidence base is extremely limited, speculative, or unsuitable for firm conclusions.
Scope
The grade evaluates the evidence supporting the specific category or claim. A grade does not evaluate product purity, supplier quality, personal suitability, treatment appropriateness, individual outcomes, legality, or medical safety for a specific person.
These grades and confidence levels describe the research evidence itself. They are not medical recommendations, and they do not evaluate any specific product, supplier, or individual's situation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Retatrutide is the development molecule LY3437943, a single peptide agonist at the GIP, GLP-1, and glucagon receptors.
Sources: LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Body Weight Reduction: From Discovery to Clinical Proof of Concept; Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Supported
Early clinical pharmacokinetic findings supported once-weekly administration in subsequent trials.
Supported
In a 48-week Phase 2 randomized trial in adults with obesity or overweight plus a weight-related condition, retatrutide produced substantial dose-dependent reductions in body weight compared with placebo.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Supported
In a Phase 2 randomized trial in type 2 diabetes, retatrutide produced dose-dependent reductions in HbA1c and body weight.
Supported
In a randomized Phase 2a MASLD study, retatrutide reduced liver fat measured by MRI-PDFF.
Supported
A type 2 diabetes body-composition substudy found greater fat-mass reduction with retatrutide, while the proportion of lean-mass loss relative to total weight loss was similar to that seen with other obesity treatments.
Supported
Lilly reported phase 3 topline findings from TRIUMPH-1 showing mean weight reductions of 19.0%, 25.9%, and 28.3% at 80 weeks for the 4 mg, 9 mg, and 12 mg groups, respectively, compared with 2.2% for placebo. This is a sponsor-reported topline result and is not yet available as a peer-reviewed full publication.
Sources: TRIUMPH-1 Phase 3 topline results in obesity or overweight
Supported
Lilly reported phase 3 topline findings from TRANSCEND-T2D-1 showing average HbA1c reductions of 1.7% to 2.0% at 40 weeks across studied doses, with weight reduction also observed. This is a sponsor-reported topline result and is not yet available as a peer-reviewed full publication.
Supported
TRIUMPH-4 sponsor-reported topline findings linked retatrutide treatment with weight reduction and improved knee-pain and physical-function measures in adults with obesity or overweight and knee osteoarthritis. This is a sponsor-reported topline result and is not yet available as a peer-reviewed full publication.
Sources: TRIUMPH-4 Phase 3 topline results in obesity or overweight with knee osteoarthritis
Supported
Gastrointestinal adverse events, including nausea, diarrhoea, vomiting, and constipation, were common in retatrutide clinical trials and were generally mild to moderate in the Phase 2 diabetes study.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial; Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Supported
The Phase 2 obesity trial reported dose-dependent increases in heart rate that peaked during treatment and later declined.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Supported
Retatrutide remains investigational, and sponsor-reported topline results do not replace peer-reviewed full reports or regulatory review.
Sources: Lilly retatrutide information; TRIUMPH-1 Phase 3 topline results in obesity or overweight
Supported
A dedicated cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes (NCT06383390), is ongoing; no completed randomized cardiovascular-outcomes trial has yet established that retatrutide reduces major cardiovascular events.
Supported
The reviewed clinical program evaluates obesity, type 2 diabetes, liver fat, osteoarthritis, and related cardiometabolic outcomes; it does not test bodybuilding, athletic performance, or longevity outcomes.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial; Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Supported
Published Phase 3 evidence in type 2 diabetes confirms clinically meaningful glycaemic and body-weight effects of retatrutide monotherapy in adults inadequately controlled with diet and exercise.
Supported
Retatrutide is not FDA approved, and FDA states that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Sources: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supported
Published retatrutide trials characterize sponsor-controlled clinical-development material and do not establish the identity, quality, sterility, or clinical equivalence of independently manufactured or grey-market products sold as retatrutide.
Sources: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial; Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial; FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Retatrutide has not completed regulatory review. Products sold outside authorized clinical research are not an approved medicine and may have uncertain identity, purity, sterility, concentration, or storage history.Safety Consideration
Nausea, diarrhea, vomiting, constipation, reduced appetite, and related gastrointestinal symptoms were common in clinical trials. Frequency and treatment discontinuation varied by dose and escalation schedule.Safety Consideration
Mean heart rate increased in clinical studies. Long-term cardiovascular benefit or harm cannot be inferred from weight loss or short-term risk-marker changes, and dedicated outcome research remains incomplete.Safety Consideration
Body-composition research found proportionally greater fat-mass loss, but lean mass also decreased. Very large or rapid weight reduction can raise concerns about muscle, nutritional status, and physical function.Safety Consideration
The completed trials are not large or long enough to define uncommon risks with precision. Severe gastrointestinal illness may contribute to dehydration and kidney stress, while incretin-class concerns require continued surveillance.Safety Consideration
Most peer-reviewed evidence comes from selected adults with obesity, overweight, type 2 diabetes, or elevated liver fat. Pregnancy, pediatric use, frailty, severe organ disease, and long-term maintenance remain insufficiently characterized.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026):
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, phase 2 trial (2025): DXA analysis found greater reduction in fat mass than lean mass, while confirming that lean mass also decreased during weight reduction.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024): At 24 weeks, mean relative liver-fat changes were -42.9%, -57.0%, -81.4%, and -82.4% with 1, 4, 8, and 12 mg, versus +0.3% with placebo.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial (2023): Once-weekly 0.5-12 mg for 36 weeks produced dose-related HbA1c and body-weight reductions compared with placebo; dulaglutide was an active comparator.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023): Once-weekly 1, 4, 8, or 12 mg for 48 weeks produced dose-related weight reduction; the 12 mg group reached 24.2% mean reduction under the efficacy estimand.
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept (2022): Single- and multiple-ascending-dose research found a pharmacokinetic profile compatible with once-weekly administration and early signals for glucose and weight effects.
- LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Body Weight Reduction: From Discovery to Clinical Proof of Concept (2022):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial | 2026 | Phase 3 monotherapy evidence in type 2 diabetes confirms clinically important glycaemic and body-weight effects while retatrutide remains under development. | |||
| Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, phase 2 trial | 2025 | Adults with type 2 diabetes enrolled in the phase 2 retatrutide trial | DXA analysis found greater reduction in fat mass than lean mass, while confirming that lean mass also decreased during weight reduction. | Substudy size, selected participants, imaging availability, and duration limit generalization. | |
| Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial | 2024 | 98 adults from the phase 2 obesity trial with at least 10% liver fat | At 24 weeks, mean relative liver-fat changes were -42.9%, -57.0%, -81.4%, and -82.4% with 1, 4, 8, and 12 mg, versus +0.3% with placebo. | The substudy measured imaging and biomarkers, not liver histology; gastrointestinal events were most frequent. | |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial | 2023 | Adults with type 2 diabetes inadequately controlled by diet and exercise, with or without metformin | Once-weekly 0.5-12 mg for 36 weeks produced dose-related HbA1c and body-weight reductions compared with placebo; dulaglutide was an active comparator. | Gastrointestinal adverse events were most common; heart-rate changes and the limited duration remain relevant. | |
| Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | 2023 | Adults with obesity or overweight and a weight-related condition, without diabetes | Once-weekly 1, 4, 8, or 12 mg for 48 weeks produced dose-related weight reduction; the 12 mg group reached 24.2% mean reduction under the efficacy estimand. | Gastrointestinal events were most common. Heart-rate increases and dose- or escalation-related tolerability findings were reported. | |
| LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept | 2022 | Early-phase human study with healthy participants and adults with type 2 diabetes | Single- and multiple-ascending-dose research found a pharmacokinetic profile compatible with once-weekly administration and early signals for glucose and weight effects. | Early-phase size and duration limit detection of uncommon or long-term adverse effects. | |
| LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Body Weight Reduction: From Discovery to Clinical Proof of Concept | 2022 | Established retatrutide's triple-receptor agonist identity and mechanism, with early single-dose human pharmacokinetic data. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | 2026 | FDA states retatrutide is not an FDA-approved drug and cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. | |||
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | 2024 | Adults with severe obesity and established cardiovascular disease | TRIUMPH-Outcomes is designed to determine whether retatrutide reduces serious cardiovascular events and/or worsening kidney outcomes in adults with obesity and established atherosclerotic cardiovascular disease and/or chronic kidney disease; completed cardiovascular-outcome efficacy results are not yet available. | Registry record describes planned research and cannot establish benefit or harm before results are reported. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| TRANSCEND-T2D-1 Phase 3 topline results | 2026 | Adults with early type 2 diabetes inadequately controlled with diet and exercise | Sponsor-reported results at 40 weeks found mean HbA1c reductions of 1.7% to 2.0% and dose-related weight reduction. | Sponsor topline source; complete peer-reviewed safety and subgroup detail should be incorporated when available. | |
| TRIUMPH-1 Phase 3 topline results in obesity or overweight | 2026 | Adults with obesity or overweight and at least one weight-related condition, without diabetes | Sponsor-reported results at 80 weeks found mean body-weight changes of -19.0%, -25.9%, and -28.3% with 4 mg, 9 mg, and 12 mg, compared with -2.2% for placebo. | Sponsor topline source; full peer-reviewed reporting and regulatory review remain pending. | |
| TRIUMPH-4 Phase 3 topline results in obesity or overweight with knee osteoarthritis | 2025 | Adults with obesity or overweight and knee osteoarthritis, without diabetes | Sponsor-reported results at 68 weeks found mean weight reduction of 26.4% with 9 mg and 28.7% with 12 mg, with improvements in WOMAC pain and physical function. | Sponsor topline source; full peer-reviewed methods and detailed safety tables were not yet the basis of this record. | |
| Lilly retatrutide information | Current | Official manufacturer information | Phase 3 development context — Confirms investigational status and active clinical trial development. | Official Lilly informational page, not a peer-reviewed publication and not a regulatory document; treat as sponsor/manufacturer-reported information. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Retatrutide is investigational and not FDA-approved for any indication discussed on this page. Content about trial dosing, outcomes, or community reports is not a recommendation to use retatrutide or any unapproved product.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Website/CMS content draft; source verification and legal/privacy review required before public launch. Last updated 2026-07-20.
Follow research updates for Retatrutide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.